CYLD and plasma cell myeloma: This high-throughput analysis identified homozygous deletions in 32 genes, including CYLD and TRAF3. Similarly, 17% of the 463 patients enrolled in the National Cancer Research Institute (UK) Myeloma XI trial possessed NF-κB-activating mutations, which affected most frequently CYLD and TRAF3 [68].